Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 329

1.

Current Practice Preferences and Safety Protocols for Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents.

Uhr JH, Xu D, Rahimy E, Hsu J.

Ophthalmol Retina. 2019 Aug;3(8):649-655. doi: 10.1016/j.oret.2019.03.013. Epub 2019 Mar 22.

PMID:
31068264
2.

Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.

Obeid A, Su D, Patel SN, Uhr JH, Borkar D, Gao X, Fineman MS, Regillo CD, Maguire JI, Garg SJ, Hsu J.

Ophthalmology. 2019 Mar;126(3):407-413. doi: 10.1016/j.ophtha.2018.07.027. Epub 2018 Aug 2.

PMID:
30077614
3.

Use of Molecular Profiling to Guide Treatment Decisions in Patients with Neuroendocrine Tumors: Preliminary Results.

Cutler HS, Ogando P, Uhr JH, Gonzalez DO, Warner RR, Divino CM.

Am Surg. 2016 Apr;82(4):369-75.

PMID:
27097632
4.

Racial Disparities in Clinical Presentation and Surgical Outcomes in Patients with Small Bowel Carcinoid Tumors.

Uhr JH, Shah J, Warner RR, Divino CM.

Am Surg. 2016 Apr;82(4):E89-92. No abstract available.

PMID:
27097615
5.

Awareness and Knowledge of Emergent Ophthalmic Disease Among Patients in an Internal Medicine Clinic.

Uhr JH, Mishra K, Wei C, Wu AY.

JAMA Ophthalmol. 2016 Apr;134(4):424-31. doi: 10.1001/jamaophthalmol.2015.6212.

PMID:
26892039
6.

Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.

Khan TM, Garg M, Warner RR, Uhr JH, Divino CM.

Pancreas. 2016 Aug;45(7):1032-5. doi: 10.1097/MPA.0000000000000572.

PMID:
26684860
8.

Laparoscopic resection of gastric and small bowel gastrointestinal stromal tumors: 10-year experience at a single center.

Tabrizian P, Sweeney RE, Uhr JH, Nguyen SQ, Divino CM.

J Am Coll Surg. 2014 Mar;218(3):367-73. doi: 10.1016/j.jamcollsurg.2013.11.029. Epub 2013 Dec 2.

PMID:
24559952
9.
10.

Immunomagnetic nanoscreening of circulating tumor cells with a motion controlled microfluidic system.

Huang YY, Hoshino K, Chen P, Wu CH, Lane N, Huebschman M, Liu H, Sokolov K, Uhr JW, Frenkel EP, Zhang JXJ.

Biomed Microdevices. 2013 Aug;15(4):673-681. doi: 10.1007/s10544-012-9718-8.

11.

Challenges in the enumeration and phenotyping of CTC.

Coumans FA, Ligthart ST, Uhr JW, Terstappen LW.

Clin Cancer Res. 2012 Oct 15;18(20):5711-8. doi: 10.1158/1078-0432.CCR-12-1585. Epub 2012 Sep 25.

12.

Associative learning in the dengue vector mosquito, Aedes aegypti: avoidance of a previously attractive odor or surface color that is paired with an aversive stimulus.

Menda G, Uhr JH, Wyttenbach RA, Vermeylen FM, Smith DM, Harrington LC, Hoy RR.

J Exp Biol. 2013 Jan 15;216(Pt 2):218-23. doi: 10.1242/jeb.074898. Epub 2012 Sep 20.

13.

Molecular profiling of individual tumor cells by hyperspectral microscopic imaging.

Uhr JW, Huebschman ML, Frenkel EP, Lane NL, Ashfaq R, Liu H, Rana DR, Cheng L, Lin AT, Hughes GA, Zhang XJ, Garner HR.

Transl Res. 2012 May;159(5):366-75. doi: 10.1016/j.trsl.2011.08.003. Epub 2011 Sep 3.

14.

Microchip-based immunomagnetic detection of circulating tumor cells.

Hoshino K, Huang YY, Lane N, Huebschman M, Uhr JW, Frenkel EP, Zhang X.

Lab Chip. 2011 Oct 21;11(20):3449-57. doi: 10.1039/c1lc20270g. Epub 2011 Aug 24.

15.

Controversies in clinical cancer dormancy.

Uhr JW, Pantel K.

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12396-400. doi: 10.1073/pnas.1106613108. Epub 2011 Jul 11. Review.

16.

Handheld histology-equivalent sectioning laser-scanning confocal optical microscope for interventional imaging.

Kumar K, Avritscher R, Wang Y, Lane N, Madoff DC, Yu TK, Uhr JW, Zhang X.

Biomed Microdevices. 2010 Apr;12(2):223-33. doi: 10.1007/s10544-009-9377-6.

PMID:
20012209
17.

Circulating tumor cells in breast cancer: fiction or reality?

Cristofanilli M, Reuben J, Uhr J.

J Clin Oncol. 2008 Jul 20;26(21):3656-7; author reply 3657-8. doi: 10.1200/JCO.2008.18.0356. No abstract available.

PMID:
18640950
18.

uPAR and HER2 Genes Are Usually Co-Amplified in Individual Breast Cancer Cells from Blood and Tissues.

Uhr J.

Breast Care (Basel). 2008;3(s2):16-19. Epub 2008 Oct 16. No abstract available.

19.

Cancer diagnostics: one-stop shop.

Uhr JW.

Nature. 2007 Dec 20;450(7173):1168-9. No abstract available.

PMID:
18097389
20.
21.

Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate.

Rabinovsky R, Uhr JW, Vitetta ES, Yefenof E.

Adv Cancer Res. 2007;97:189-202. Review.

PMID:
17419946
22.

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LW, Lane N, Wang J, Uhr J.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17361-5. Epub 2006 Nov 1.

23.

Cancer dormancy: from mice to man.

Marches R, Scheuermann R, Uhr J.

Cell Cycle. 2006 Aug;5(16):1772-8. Epub 2006 Aug 15. Review.

PMID:
16929181
24.

Circulating tumor cells in patients with breast cancer dormancy.

Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW.

Clin Cancer Res. 2004 Dec 15;10(24):8152-62.

25.

Mathematical models of cancer dormancy.

Page K, Uhr JW.

Leuk Lymphoma. 2005 Mar;46(3):313-27. Review.

PMID:
15621821
26.

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW.

Clin Cancer Res. 2004 Oct 15;10(20):6897-904.

28.

HER-2 gene amplification can be acquired as breast cancer progresses.

Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J.

Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8. Epub 2004 Jun 11.

29.

Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes.

Hsueh RC, Hammill AM, Lee JA, Uhr JW, Scheuermann RH.

BMC Immunol. 2002 Dec 6;3:16. Epub 2002 Dec 6.

30.

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.

Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C, Doyle GV, Terstappen LW.

Int J Oncol. 2002 Nov;21(5):1111-7.

PMID:
12370762
31.

Patterns of aneusomy for three chromosomes in individual cells from breast cancer tumors.

Fehm T, Morrison L, Saboorian H, Hynan L, Tucker T, Uhr J.

Breast Cancer Res Treat. 2002 Oct;75(3):227-39.

PMID:
12353812
32.

Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.

Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C, Uhr J.

Clin Cancer Res. 2002 Jul;8(7):2073-84.

33.

Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.

Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES.

Clin Cancer Res. 2002 Jun;8(6):1720-30.

34.

[Interphase cytogenetics with DNA-probes for chromosome 8 to detect circulating tumor cells in breast cancer patients].

Ghadimi BM, Uhr J, Tucker T, Heselmeyer-Haddad K, Auer G, Ried T, Becker H.

Zentralbl Chir. 2001 Nov;126(11):922-5. German.

PMID:
11753805
35.

Dormancy in a model of murine B cell lymphoma.

Uhr JW, Marches R.

Semin Cancer Biol. 2001 Aug;11(4):277-83. Review.

PMID:
11513563
36.

A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas.

Marches R, Vitetta ES, Uhr JW.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3434-9. Epub 2001 Feb 27.

38.

Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death.

Hammill AK, Uhr JW, Scheuermann RH.

Exp Cell Res. 1999 Aug 25;251(1):16-21.

PMID:
10438567
39.
40.

Antigen receptor signaling induces differential tyrosine kinase activation and population stability in B-cell lymphoma.

Hsueh RC, Hammill AK, Marches R, Uhr JW, Scheuermann RH.

Curr Top Microbiol Immunol. 1999;246:299-304; discussion 305. Review. No abstract available.

PMID:
10396069
41.

Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state.

Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, Street NE.

J Immunol. 1999 Mar 1;162(5):2842-9.

42.

Flow cytometry--principles and feasibility in transfusion medicine. Enumeration of epithelial derived tumor cells in peripheral blood.

Terstappen LW, Rao C, Gross S, Kotelnikov V, Racilla E, Uhr J, Weiss A.

Vox Sang. 1998;74 Suppl 2:269-74. Review.

PMID:
9704456
43.

Detection and characterization of carcinoma cells in the blood.

Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW.

Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4589-94.

44.
45.

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.

Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES.

Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7509-14.

46.

Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established.

Vitetta ES, Tucker TF, Racila E, Huang YW, Marches R, Lane N, Scheuermann RH, Street NE, Watanabe T, Uhr JW.

Blood. 1997 Jun 15;89(12):4425-36.

47.

Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.

Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, Figg WD, Lush RM, Stetler-Stevenson M, Kershaw G, Kingma DW, Jaffe ES, Sausville EA.

Ann Intern Med. 1997 Jun 1;126(11):882-5. No abstract available.

PMID:
9163289
48.

Cancer dormancy: opportunities for new therapeutic approaches.

Uhr JW, Scheuermann RH, Street NE, Vitetta ES.

Nat Med. 1997 May;3(5):505-9. Review. No abstract available.

PMID:
9142117
49.

A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.

Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schön G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J, Vitetta E.

Blood. 1997 Jan 15;89(2):403-10.

50.

Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins.

Baluna R, Sausville EA, Stone MJ, Stetler-Stevenson MA, Uhr JW, Vitetta ES.

Clin Cancer Res. 1996 Oct;2(10):1705-12.

Supplemental Content

Support Center